Trulieve Cannabis (NYSE:TRLV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Trulieve Cannabis (NYSE:TRLV) announced its quarterly earnings results on Friday. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05, Zacks reports. The firm had revenue of $271.00 million for the quarter, compared to analysts’ expectations of $268.82 million.

Here are the key takeaways from Trulieve Cannabis’ conference call:

• Core profitability and cash flow remained strong: Medical-only revenue rose 4% sequentially to $222 million, with a 63% gross margin and $98 million of adjusted EBITDA at a 36% margin. Operating cash flow was $53 million, while quarter-end cash totaled $325 million versus $289 million of debt.
• Georgia is emerging as a significant growth driver: Expanded qualifying conditions and product formats drove a sharp increase in traffic, while patient enrollment surpassed 45,000. Trulieve is expanding cultivation, adding dispensaries, and supplying nearly 20 independent pharmacies, although temporary flower shortages constrained sales.
• Texas offers substantial expansion potential: Trulieve is converting its conditional license to final approval and has completed initial production construction. Management sees considerable upside as the program expands beyond 157,000 patients, with plans to scale production and retail locations alongside demand.
• Reported results and full-year cash-flow guidance were affected by the Harvest deconsolidation: The company posted a $406 million GAAP net loss, including a $407 million impact from the transaction, although adjusted results would have shown $20 million of net income. Full-year operating cash-flow guidance was reduced to at least $225 million, while capital-expenditure guidance increased to $95 million as Trulieve invests in growth.

Trulieve Cannabis Price Performance

TRLV stock opened at $8.76 on Friday. Trulieve Cannabis has a 1 year low of $4.62 and a 1 year high of $13.28.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. Wall Street Zen lowered Trulieve Cannabis from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings started coverage on Trulieve Cannabis in a research report on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of Trulieve Cannabis in a research report on Friday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $15.00.

Insider Transactions at Trulieve Cannabis

In other Trulieve Cannabis news, CEO Kim A. Rivers sold 136,811 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $8.76, for a total value of $1,198,464.36. Following the completion of the sale, the chief executive officer directly owned 1,476,913 shares of the company’s stock, valued at $12,937,757.88. This trade represents a 8.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,699,007 shares of company stock valued at $14,661,355. 3.79% of the stock is owned by corporate insiders.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.